Status:
COMPLETED
Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7 Abnormalities After Immunosuppressive Therapy
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Severe Aplastic Anemia
Eligibility:
All Genders
2+ years
Brief Summary
Background: Severe aplastic anemia (SAA) is a form of bone marrow failure. It usually results from a cytotoxic T cell attack on the marrow stem cell. Two treatments can be used for SAA. One is allog...
Detailed Description
Severe aplastic anemia (SAA) is a form of bone marrow failure in most cases is the result of a cytotoxic T cell attack on the marrow stem cell. It is effectively treated in most patients with either i...
Eligibility Criteria
Inclusion
- Subjects will not be recruited for this study. This is a retrospective chart review.
- Patients who opted out of future use of data on their prior studies will be excluded from this study.
Exclusion
Key Trial Info
Start Date :
June 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 15 2022
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04436367
Start Date
June 15 2020
End Date
March 15 2022
Last Update
September 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States, 20892